Research and Markets (http://www.researchandmarkets.com/research/ab4b51/whos_developing_w) has announced the addition of the "Who’s Developing What in Global Biopharmaceuticals?" report to their offering.
A critical assessment of 50 leading companies, their research, products, partners and performance.
The biopharmaceutical R&D sector is taking an ever more important role in the minds of industry and investors. The potential to fundamentally alter treatment regimes and cure, rather than symptomatically treat, many life-threatening conditions grows greater, but questions remain:
- Who are the companies that are leading development in this critical area?
- What is their area of expertise?
- How substantial is their current product line-up or pipeline projects?
- With whom are they collaborating?
- How can you assess their strengths and weaknesses?
Who’s Developing What in Global Biopharmaceuticals? is a new 475 page management guide to 50 significant companies working in the field. From their structure, through collaboration and detailed pipeline evaluation, the report provides an unmatchable window to the future biopharmaceutical corporate environment.
Answering key questions such as...
- With which major pharmaceutical companies is French company Evotec working, and on what?
- Optimer Pharmaceuticals has eight products in development – what stage are they at and for what are they indicated?
- What benefit has Astex Therapeutics’ Pyramid drug discovery platform brought to the company?
Key Topics Covered: An Analysis of the Below Companies Mentioned. Important areas covered, where available, for each company include: - Key Personnel - List of key management - Company Overview - Milestones - Summary table of key events in the company's history - R&D Pipeline - Products/research by phase and indication - Technology - Novel discovery/production technology platforms - Agreements - Who's working with whom? Important alliances identified - Key Financial Data - Essential P&L/funding data - Appraisal & Evaluation - A critical assessment of the company's platform, pipeline and corporate environment
Companies Mentioned: - Affymax - Ambit Biosciences - Ambrx - Amylin Pharmaceuticals - Arana Therapeutics - ARCA biopharma - ARIUS Research - ARYx Therapeutics - Astex Therapeutics - BioVex - BioXell - Bruin Pharmaceuticals - Cellectis - CombinatoRx - Deltanoid Pharmaceuticals - Diatos - Evotec - FivePrime Therapeutics - Genmab A/S - Idenix Pharmaceuticals - Ikaria - Infinity Pharmaceuticals - Intercytex - Ironwood Pharmaceuticals - KAI Pharmaceuticals - Kalypsys - Kereos - Micromet - Molecular Insight Pharmaceuticals - Neuromed Pharmaceuticals - Novexel - NPS Pharmaceuticals - Optimer Pharmaceuticals - Palatin Technologies - PharmaMar - Prana Biotechnology - Replidyne - S*BIO - Sosei - Speedel Pharmaceuticals - Synta Pharmaceuticals - Syntaxin - Takara Bio - Theravance - Tranzyme Pharma - Trimeris - Trubion Pharmaceuticals - ViroPharma - WILEX - Xencor
For more information visit http://www.researchandmarkets.com/research/ab4b51/whos_developing_w
Source: Espicom Business Intelligence Ltd
Contacts:
Laura Wood, Senior Manager
U.S. Fax:
646-607-1907
Fax (outside U.S.): +353-1-481-1716
press@researchandmarkets.com
